ResMed Inc. (NYSE:RMD) Director Witte Jan De Sells 360 Shares

ResMed Inc. (NYSE:RMDGet Free Report) Director Witte Jan De sold 360 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $218.29, for a total transaction of $78,584.40. Following the sale, the director now directly owns 7,519 shares in the company, valued at $1,641,322.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

ResMed Trading Down 0.6 %

Shares of RMD stock traded down $1.40 on Friday, hitting $218.57. 450,553 shares of the stock traded hands, compared to its average volume of 1,198,189. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.97 and a current ratio of 3.04. ResMed Inc. has a twelve month low of $132.24 and a twelve month high of $229.97. The firm’s 50-day moving average price is $197.71 and its two-hundred day moving average price is $179.80. The stock has a market capitalization of $32.11 billion, a PE ratio of 33.57, a PEG ratio of 2.70 and a beta of 0.64.

ResMed (NYSE:RMDGet Free Report) last posted its earnings results on Thursday, April 25th. The medical equipment provider reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.22. The company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. ResMed had a net margin of 20.91% and a return on equity of 24.43%. ResMed’s revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.68 EPS. As a group, analysts anticipate that ResMed Inc. will post 7.64 EPS for the current year.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 13th. Investors of record on Thursday, May 9th will be given a $0.48 dividend. The ex-dividend date is Wednesday, May 8th. This represents a $1.92 annualized dividend and a yield of 0.88%. ResMed’s payout ratio is 29.49%.

Institutional Investors Weigh In On ResMed

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wahed Invest LLC raised its stake in shares of ResMed by 15.5% in the 1st quarter. Wahed Invest LLC now owns 2,862 shares of the medical equipment provider’s stock valued at $567,000 after acquiring an additional 384 shares during the period. Plato Investment Management Ltd raised its position in ResMed by 79,500.0% in the first quarter. Plato Investment Management Ltd now owns 3,184 shares of the medical equipment provider’s stock valued at $631,000 after purchasing an additional 3,180 shares during the period. iA Global Asset Management Inc. purchased a new stake in ResMed in the first quarter valued at approximately $3,055,000. Tidal Investments LLC boosted its position in shares of ResMed by 58.2% during the first quarter. Tidal Investments LLC now owns 8,954 shares of the medical equipment provider’s stock worth $1,773,000 after buying an additional 3,294 shares during the period. Finally, Motley Fool Asset Management LLC grew its stake in shares of ResMed by 12.6% in the first quarter. Motley Fool Asset Management LLC now owns 4,950 shares of the medical equipment provider’s stock valued at $980,000 after buying an additional 553 shares in the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on RMD shares. Mizuho restated a “buy” rating and set a $215.00 target price on shares of ResMed in a research report on Wednesday, March 27th. Royal Bank of Canada lifted their price target on ResMed from $187.00 to $200.00 and gave the stock a “sector perform” rating in a research note on Friday, April 26th. KeyCorp boosted their price target on ResMed from $227.00 to $238.00 and gave the stock an “overweight” rating in a research report on Friday, April 26th. Oppenheimer decreased their price objective on ResMed from $205.00 to $200.00 and set an “outperform” rating on the stock in a report on Friday, April 26th. Finally, UBS Group upped their target price on shares of ResMed from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $202.80.

Get Our Latest Report on RMD

About ResMed

(Get Free Report)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Read More

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.